JPMorgan Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)

August 19, 2025 7:26 AM EDT Send to a Friend
JPMorgan analyst Tessa Romero reiterated an Overweight rating and $30.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst commented, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login